8-K - ENDV - Equibles

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CURRENTREPORT

PURSUANTTO SECTION 13 OR 15(d) OF THE

SECURITIESEXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 6, 2020

ENDONOVOTHERAPEUTICS, INC.

(Exactname of registrant as specified in its charter)

Delaware	000-55453	45-2552528
(State or other jurisdiction<br> <br><br>of incorporation)	(Commission<br><br> File<br> Number)	(IRS Employer<br><br> Identification<br> No.)

6320Canoga Avenue, 15^th^ Floor

WoodlandHills, CA 91367

(Address of principal executive office)(Zip Code)

Registrant’s telephone number, including area code: (800) 489-4774

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant<br> to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12<br> under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to<br> Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to<br> Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title<br> of each class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangementsof Certain Officers.

On August 6, 2020, the registrant’s president, Michael Mann resigned. Mr. Mann’s resignation was not due to any disagreements with the registrant.

A copy of Mr. Mann’s resignation letter is attached hereto.

Item9.01 Financial Statements and Exhibits.

(a)	Financial<br> Statements

None

(b) Exhibits

No.	Description
99.1	Resignation letter from Michael Mann, dated August 6, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2020

ENDONOVO THERAPEUTICS, INC.
By:	/s/ Alan Collier
	Alan Collier
	Chief Executive Officer

Exhibit99.1

August 6, 2020

Dear Alan,

Please except my resignation as President effective immediately.

My resignation is for personal reasons and not due to any disagreements with the Company or its policies.

I wish you and the company the greatest success for all the investors and of course, for my personal investments as well.

If I can be of service, please call on me.

Michael Mann